Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 6/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926592 | 0.91 | ADRA1A (0.52) | ADRA1AADRA1BADRA1DHTR1ASLC6A4 | |
| SCHEMBL7344989 | 0.86 | HTR1A (0.64) | ADRA1AADRA1BADRA1DHTR1ADRD2 | |
| SCHEMBL6924603 | 0.84 | DRD3 (0.55) | HTR1ADRD2DRD3 | |
| SCHEMBL7351802 | 0.84 | HTR1A (0.58) | ADRA1AADRA1BADRA1DHTR1ASLC6A4 | |
| SCHEMBL7344855 | 0.81 | DRD2 (0.63) | ADRA1AADRA1BADRA1DHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL7347501 | 0.79 | DRD2 (0.62) | ADRA1AADRA1BADRA1DHTR1ADRD2 | |
| SCHEMBL7068893 | 0.78 | KCNH2 (0.64) | HTR1ADRD2DRD3 | |
| SCHEMBL6926353 | 0.78 | ADRA1A (0.51) | ADRA1AADRA1BADRA1DHTR1ASLC6A4 | |
| SCHEMBL5813172 | 0.78 | ADRA1A (0.61) | ADRA1AADRA1BADRA1DHTR1ADRD2 | |
| SCHEMBL5808327 | 0.77 | DRD2 (0.77) | ADRA1AADRA1BADRA1DHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | H. LUNDBECK A/S (DE) | 2003-06-26 | — | — | US | disclosed |
| US-6514993-B1 | Useful in the treatment of certain psychic and neurologic disorders | H. LUNDBECK A/S (DK) | 2003-02-04 | — | — | US | disclosed |
| EP-0770066-B1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | LUNDBECK & CO AS H (DK) | 2000-05-17 | — | — | EP | disclosed |
| EP-0770066-A1 | SEROTONIN 5-HT 1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1997-05-02 | — | — | EP | disclosed |
| WO-1995033729-A1 | SEROTONIN 5-HT1A AND DOPAMIN D2 RECEPTOR LIGANDS | H. LUNDBECK A/S (DK) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120070-A1 | Serotonin 5-HT1A and dopamin D2 receptor ligands | HTR5A, HTR2C, HTR1D | ADRA1A 110/4885ADRA1B 129/4885ADRA1D 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.